Prospective, multicentre, randomised controlled trial comparing the seroclearance of HBsAg between combination therapy of peg-interferon alpha and tenofovir with tenofovir monotherapy in nucleos(t)ide analogue-experienced patients with HBV-related liver fibrosis: a study protocol

INTRODUCTION: Combination antiviral therapy of nucleos(t)ide analogue (NA) and pegylated interferon alpha (peg-IFN alpha) decrease hepatitis B virus (HBV) surface antigen (HBsAg) levels to achieve functional cure and improve long-term prognosis in chronic hepatitis B patients. However, for hepatitis...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Shu, Wu, Lina, Mei, Yongyu, Liu, Zhihua, Lin, Luping, Yuan, Jing, Li, Jianguo, Li, Xuejun, Peng, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547364/
https://www.ncbi.nlm.nih.gov/pubmed/34697111
http://dx.doi.org/10.1136/bmjopen-2021-049104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547364/
https://www.ncbi.nlm.nih.gov/pubmed/34697111
http://dx.doi.org/10.1136/bmjopen-2021-049104

Ejemplares similares